论文部分内容阅读
目的探讨细胞周期蛋白D1(cyclin D1)与雌激素受体(ER)在乳腺癌中的表达和临床意义。方法采用免疫组织化学方法检测102例乳腺癌组织和60例正常乳腺组织标本中cyclin D1及ER蛋白表达,结合临床病理及术后5年随访资料,分析cyclin D1与ER相关性及与预后之间的关系。结果与正常乳腺组织相比,乳腺癌组织中cyclin D1和ER表达显著性增加,且cyclin D1表达与肿瘤组织学分级、TNM分期、ER蛋白表达相关。Spearman相关性分析显示,cyclin D1与ER表达水平呈正相关。Kaplan-Meier生存分析发现,cyclin D1高表达组乳腺癌患者生存期明显高于低表达组。Cox多因素分析表明cyclin D1、ER及TNM分期是影响患者预后的独立因素。结论 Cyclin D1在乳腺癌组织高表达,与ER表达正相关,且指示良好的预后。
Objective To investigate the expression and clinical significance of cyclin D1 and estrogen receptor (ER) in breast cancer. Methods The expressions of cyclin D1 and ER in 102 cases of breast cancer tissues and 60 cases of normal breast tissues were detected by immunohistochemistry. The correlation between cyclin D1 and ER and the prognosis were analyzed according to the clinicopathological features and follow-up data of 5 years after operation. Relationship. Results Compared with normal breast tissue, the expression of cyclin D1 and ER in breast cancer tissues was significantly increased, and the expression of cyclin D1 was correlated with histological grade, TNM stage and ER protein expression. Spearman correlation analysis showed that there was a positive correlation between cyclin D1 and ER expression. Kaplan-Meier survival analysis found that patients with high expression of cyclin D1 breast cancer survival was significantly higher than the low expression group. Cox multivariate analysis showed that cyclin D1, ER and TNM staging were independent prognostic factors. Conclusions Cyclin D1 is highly expressed in breast cancer tissues and positively correlates with ER expression, indicating a good prognosis.